11,346 Shares in Johnson & Johnson $JNJ Purchased by NBH Bank

Key Points

• NBH Bank initiated a $2.88 million position in Johnson & Johnson during the second quarter, buying 11,346 shares. J&J now represents approximately 1.2% of the bank’s portfolio, while institutional investors and hedge funds collectively own 69.55% of the stock.
• Johnson & Johnson recently exceeded earnings and revenue expectations, with quarterly EPS of $2.90 and revenue of $25.31 billion, up 6.6% year over year. The company also maintains a $1.34 quarterly dividend, equivalent to a 2.0% yield.
• Shares trade near their 12-month high at a P/E ratio of about 30.8, prompting some valuation and momentum concerns despite positive product developments and a consensus analyst rating of “Moderate Buy”.

NBH Bank purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,346 shares of the company's stock, valued at approximately $2,882,000. Johnson & Johnson makes up approximately 1.2% of NBH Bank's holdings, making the stock its 18th biggest holding.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. State Street Corp raised its stake in Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company's stock valued at $27,704,364,000 after buying an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co raised its stake in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Geode Capital Management LLC lifted its holdings in Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company's stock worth $11,967,947,000 after acquiring an additional 1,738,292 shares during the last quarter. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter worth about $6,924,523,000. Finally, Wellington Management Group LLP boosted its stake in Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock valued at $4,789,914,000 after acquiring an additional 956,239 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
• Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
• Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 87,569 shares of company stock worth $23,064,544 in the last quarter. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $265.91 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm's 50 day moving average is $263.03 and its 200-day moving average is $245.93. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $281.07. The stock has a market capitalization of $640.82 billion, a P/E ratio of 30.81, a P/E/G ratio of 2.54 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the business posted $2.77 earnings per share. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is currently 62.11%.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. Citigroup increased their price objective on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. TD Cowen increased their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a report on Monday, July 13th. Wells Fargo & Company raised their target price on Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. The Goldman Sachs Group reiterated a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, HSBC increased their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $274.13.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.